Spots Global Cancer Trial Database for A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Official Title: A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
Study ID: NCT04171700
Conditions
Interventions
Study Description
Brief Summary: A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Medicine Hematology and Oncology, Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Cancer Specialists, Saint Petersburg, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
University of Iowa Hospital and Clinics, Iowa City, Iowa, United States
Beth Israel Deaconess Medical Cancer Surgical Pavilion, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
New York Cancer And Blood Specialists, Bronx, New York, United States
Columbia University Irving Medical Center, New York, New York, United States
New York Cancer and Blood Specialists, Port Jefferson Station, New York, United States
Ohio State University, Columbus, Ohio, United States
Stephenson Cancer Center - The University of Oklahoma, Oklahoma City, Oklahoma, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
SCRI/Tennessee Oncology - Chattanooga, Chattanooga, Tennessee, United States
Tennessee Oncology, Nashville, Tennessee, United States
Seattle Cancer Care Alliance/University of Washington, Seattle, Washington, United States
Contact Details
Name: Kim Reiss-Binder, MD
Affiliation: University of Pennsylvania
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
